Kerri Gulley

Kerri Gulley is a seasoned professional in the pharmaceutical sector, currently serving as Senior Global Category Manager for R&D Clinical at Alnylam Pharmaceuticals since November 2014. In this role, Kerri manages the outsourcing of early-phase clinical trials, regulatory affairs, pharmacovigilance, and medical writing services, overseeing a substantial $230 million in R&D Clinical expenditure for 2023 while driving strategic initiatives across a growing pipeline. Previous positions include Procurement Specialist at SeraCare Life Sciences, where Kerri led global research studies for diagnostic device development, and QC Analyst at New England Testing Laboratory, focusing on environmental analysis for heavy metals. Kerri holds a BS in Microbiology from the University of Rhode Island and a BA in Biology from Rhode Island College.